Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a…

By Mitchell Dowsett, Jack Cuzick, C. Wale, J. Forbes, E. Mallon, J. Salter, E. Quinn, A. Dunbier, M. Baum, A. Buzdar and 4 more. Journal of Clinical Oncology, 2010

713 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7e21367b4f787578e2fdf3ad689f06cccfd93d2f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Mitchell Dowsett
2. Ian O. Ellis
3. Zhonghu Bai
4. Xiaofeng Dai
5. H. Horlings

In Genetics

1. Mitchell Dowsett
2. Lisa M. McShane
3. Xiaofeng Dai

In Pulmonary and Respiratory Medicine

1. H. Horlings

Citations in the corpus

• Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. (2011, methodology): “We recently reported that the Genomic Health recurrence score (GHI-RS), also known as Oncotype Dx, provided additional prognostic information regarding distant recurrence beyond that obtained from classical clinicopathologic factors (age, nodal status, tumor size, grade, randomized treatment) in 1,2”
• Breast cancer intrinsic subtype classification, clinical use and future trends. (2015, background): “Also, evidences show that the recurrence score has predictive value among ER positive patients treated with aromatase inhibitors [55], and is prognostic of patients with ER positive tumors harboring up to three positive lymph nodes [56].”
• Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, background): “Group (SWOG) S8814 and Arimidex, Tamoxifen, Alone or in Combination (ATAC) trials suggest that patients with only one to three positive nodes may have similar prognoses to those with negative nodes.(22,23) However, the panel could not rule out the possibility of additional variation in prognosis due”